ArticleTherapeutic advances in medical oncology2021

Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab

Robert Hettle et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.